Related stories
AN2 Therapeutics Reports Third-Quarter Loss of $7.96 Million
M impact | EQUITY | Nov 09, 2026, 12:33 PM UTC
Foghorn Therapeutics Q3 Collaboration Revenue Jumps on Catch-Up Adjustment
M impact | EQUITY | Nov 09, 2026, 12:31 PM UTC
Olectra Greentech Q2 Net Profit Rises 6.8% to ₹53 Crore
Consolidated net profit increased 6.8% year on year to ₹52.93 crore, while revenue from operations rose 4.6% to ₹687 crore.
M impact | EQUITY | Nov 09, 2026, 12:31 PM UTC
ADC Therapeutics Reports Third-Quarter 2026 Results, Operational Updates
ADC Therapeutics reported $21 million in third-quarter net product revenue and $189.2 million in cash and cash equivalents as of September 30, 2026. The company said a financial re
M impact | EQUITY | Nov 09, 2026, 12:31 PM UTC
European session market picture: S&P 500 +0.6%, Nasdaq 100 +0.48%; EUR/USD +0.43%, WTI -2.92%, LLOY leads volume
European session market picture. US index futures: S and P futures is up 0.6 percent, Nasdaq futures is up 0.48 percent, Dow futures is up 0.96 percent and Russell futures is up 1.
M impact | EQUITY | Nov 09, 2026, 12:31 PM UTC
ADC Therapeutics reports third-quarter loss per share
M impact | EQUITY | Nov 09, 2026, 12:30 PM UTC